Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/25/2025

Qsymia Prescribing Considerations in Elderly Patients

  • The American Gastroenterological Association notes that clinical trial data for Qsymia only extend to age 70 years, and caution is warranted in elderly patients due to limited safety data in this population 1
  • The American College of Physicians recommends Qsymia for adults 18 years and older with obesity or overweight with weight-related comorbidities 2, 3

Critical Geriatric Prescribing Adjustments

  • The American Heart Association advises avoiding Qsymia in patients with a history of cardiovascular disease or uncontrolled hypertension, conditions more prevalent in older adults 1
  • The American College of Cardiology notes that phentermine/topiramate causes a small increase in heart rate, which may be poorly tolerated in elderly patients with cardiac comorbidities 1
  • The National Institute on Aging states that no large cardiovascular outcome trial data exist for long-term use of Qsymia, making risk assessment in elderly patients with existing cardiovascular disease challenging 1

Practical Clinical Algorithm for Elderly Patients

  • The American Geriatrics Society recommends screening cardiovascular history and excluding patients with prior cardiovascular events or uncontrolled hypertension before prescribing Qsymia 1
  • The National Kidney Foundation advises monitoring serum bicarbonate regularly due to the risk of metabolic acidosis, which elderly patients may tolerate poorly 4
  • The American College of Clinical Pharmacy recommends starting Qsymia at the lowest dose and titrating slowly, and monitoring heart rate and blood pressure at each titration step 4, 5
  • The American Society for Metabolic and Bariatric Surgery notes that Qsymia must be discontinued at least 4 days before procedures requiring general anesthesia due to perioperative complications 4